What is in Store?
Time: 5:52 pm
day: Day One
Details:
Engage with your IPF community’s foremost thought leaders and pioneering figures in a laid-back setting, fostering ongoing dialogues and delve deeper into the ground-breaking insights exchanged earlier in the day. Benefit from the perspectives of industry trailblazers, and fearlessly pose insightful questions to extract forward-thinking insights that will influence the future landscape of IPF treatments.
Panel Discussion: Interrogating Recent Phase 2 & Phase 3 Failures by Dissecting Targets & MOA & Chosen Biomarkers, Endpoints, Patient Populations & Beyond to Bridge the Late Translational Gap
The last 12 months have been a turbulent year with high profile and unexpected clinical failures whereby Galecto and FibroGen’s phase 2 and phase 3 trials both failed to meet their primary endpoint of lung function (FVC). Having both showed immense promise experts in the space really can’t place their bets as where the next approval is coming from when these candidates looked so promising until late-stage clinical trials. Therefore, there is the opportunity to double down on the challenges and learn from these clinical failures and take the lessons learned into current therapeutic development.
